Our upgraded Sample Overview dashboard is now standard for all partners. It replaces a simple pass/fail with a robust, multi-factor score that checks post-thaw cell count post-thaw viability percentage, live singlets acquired, and non-granulocytes acquired. This allows developers to instantly assess sample quality and read direct scientist comments, enabling faster, more confident decisions
For clinical trial leaders, the enhanced dashboard provides immediate, transparent insights into sample integrity, ensuring greater data reliability.
A simplistic "pass/fail" on a clinical trial sample, often based on a single metric like total events, can hide critical issues and create data uncertainty that puts project timelines at risk.
Our new dashboard provides deeper clarity by verifying four critical metrics for a more reliable QC status. For example, depending on the sample type (PBMC vs. Whole Blood) and the processing method (Spectral vs. Mass), there are different values associated with the four QC metrics. For example, with PBMCs processed on a mass cytometry panel, the criteria would be based off the following values: (>700k for cell count post thaw), >=80% Viability Post Thaw, >=50,000 events for Live singlets acquired, and non-granulocytes (>25k).
This multi-gate system introduces a ‘Partial Pass’ status for added nuance. If a sample fails the post-thaw QC metrics but passes the live singlets and non-granulocyte thresholds, that sample is considered a partial pass. Direct comments from our scientists provide essential context for any flagged samples, turning the QC process from a black box into a transparent, trustworthy tool.
The comments section also allows scientists to mark where samples experienced processing issues and provides context regarding what samples were impacted.
The enhanced Sample Overview is now live for all studies. No action is required, simply login at app.teiko.bio to view the feature release.
